Novavax, Inc.

NASDAQ:NVAX   3:59:57 PM EDT
102.48
+7.15 (+7.50%)
4:35:44 PM EDT: $102.80 +0.32 (+0.31%)
Products, Other Pre-Announcement

Novavax COVID-19 Vaccine Granted Fast Track Designation By U.S. FDA

Published: 11/09/2020 14:36 GMT
Novavax Inc (NVAX) - Novavax Covid-19 Vaccine Granted Fast Track Designation by U.S. FDA.
Novavax Inc - Novavax Expects to Begin Its Pivotal Phase 3 Clinical Trial in United States and Mexico by End of November.
Novavax Inc - Depending on Overall Covid-19 Attack Rate, Interim Data in Uk Trial, Which is Also Event-driven, Are Expected As Soon As Early Q1 2021.
Novavax Inc - Ongoing Phase 3 Trial in Uk to Evaluate Nvx-cov2373 is Expected to Be Fully Enrolled by the End of November.